Bergapten exerts inhibitory effects on diabetes-related osteoporosis via the regulation of the PI3K/AKT, JNK/MAPK and NF-κB signaling pathways in osteoprotegerin knockout mice

Li,Xue-Ju; Zhu,Zhe; Han,Si-Lin; Zhang,Zi-Long

doi:10.3892/ijmm.2016.2794

Bergapten exerts inhibitory effects on diabetes-related osteoporosis via the regulation of the PI3K/AKT, JNK/MAPK and NF-κB signaling pathways in osteoprotegerin knockout mice

Authors:
- Xue-Ju Li
- Zhe Zhu
- Si-Lin Han
- Zi-Long Zhang
View Affiliations

Affiliations: Department of Orthopaedics, Zaozhuang Municipal Hospital, Zaozhuang, Shandong 277100, P.R. China
Published online on: November 2, 2016 https://doi.org/10.3892/ijmm.2016.2794
Pages: 1661-1672
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Diabetes, as a serious metobolic disorder, poses global threat to human health. It is estimated that over 50 million individuals are already affected by diabetes. Currently, diabetes-related osteoporosis has been a research hotspot due to its high incidence rate in older individuals. Osteoprotegerin, as an important protein for the prevention of osteoporosis, has been proven to be key to the suppression of osteoporosis. Hence, the loss of function of osteoprotegerin may promote the development of osteoporosis. Bergapten, as a natural anti-inflammatory and anti-tumor agent isolated from bergamot essential oil, other citrus essential oils, and grapefruit juice, has been proven to have the ability to attenuate a number of metabolic disorders. In view of these findings, in this study, we used a high-fat diet to construct a mouse model of diabetes-related osteoporosis and a mouse model of diabetes-related osteoporosis using osteoprotegerin knockout mice. Enzyme-linked immunosorbent assay (ELISA), qPCR, western blot analysis, immunohistochemical assay, H&E staining, Oil Red O staining, Masson's staining and other biochemical analyses were used to evaluate the related signaling pathways involved in the development of diabetes-related osteoporosis. We also examined the role of osteoprotegerin in the activation of these pathways and in the development of osteoporosis, as well as the protective effects of bergapten against diabetes-related osteoporosis and on the activation of related signaling pathways. Our results revealed that in diabetes-related osteoporosis, the phosphoinositide 3-kinase (PI3K)/AKT, c-Jun N-terminal kinase (JNK)/mitogen-activated protein kinase (MAPK) and nuclear factor-κB (NF-κB) signaling pathways were activated and the expression levels of related indicators were increased. At the same time, osteoprotegerin knockout further promoted the activation of these pathways. By contrast, bergapten exerted effects similar to those of osteoprotegerin. Bergapten exhibited the ability to significantly inhibit RANKL-RANK signaling transduction, and to suppress the activation of the PI3K/AKT, JNK/MAPK and NF-κB signaling pathways, thus protecting trabecular structure and decreasing osteoclastogenic differentiation.

View Figures

View References

1	Marcus R: Post-menopausal osteoporosis. Best Pract Res Clin Obstet Gynaecol. 16:309–327. 2002. View Article : Google Scholar : PubMed/NCBI
2	Mullin BH, Prince RL, Dick IM, Hart DJ, Spector TD, Dudbridge F and Wilson SG: Identification of a role for the ARHGEF3 gene in postmenopausal osteoporosis. Am J Hum Genet. 82:1262–1269. 2008. View Article : Google Scholar : PubMed/NCBI
3	Reppe S, Refvem H, Gautvik VT, Olstad OK, Høvring PI, Reinholt FP, Holden M, Frigessi A, Jemtland R and Gautvik KM: Eight genes are highly associated with BMD variation in postmenopausal Caucasian women. Bone. 604–612. 2010. View Article : Google Scholar
4	Jemtland R, Holden M, Reppe S, Olstad OK, Reinholt FP, Gautvik VT, Refvem H, Frigessi A, Houston B and Gautvik KM: Molecular disease map of bone characterizing the postmenopausal osteoporosis phenotype. J Bone Miner Res. 26:1793–1801. 2011. View Article : Google Scholar : PubMed/NCBI
5	Chao TH, Yu HN, Huang CC, Liu WS, Tsai YW and Wu WT: Association of interleukin-1 β (−511C/T) polymorphisms with osteoporosis in postmenopausal women. Ann Saudi Med. 30:437–441. 2010.PubMed/NCBI
6	Finkelstein JS, Brockwell SE, Mehta V, Greendale GA, Sowers MR, Ettinger B, Lo JC, Johnston JM, Cauley JA, Danielson ME and Neer RM: Bone mineral density changes during the menopause transition in a multiethnic cohort of women. J Clin Endocrinol Metab. 93:861–868. 2008. View Article : Google Scholar
7	Roy DK, Berry JL, Pye SR, Adams JE, Swarbrick CM, King Y, Silman AJ and O'Neill TW: Vitamin D status and bone mass in UK South Asian women. Bone. 40:200–204. 2007. View Article : Google Scholar
8	Bone HG, Greenspan SL, McKeever C, Bell N, Davidson M, Downs RW, Emkey R, Meunier PJ, Miller SS, Mulloy AL, et al: Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group. J Clin Endocrinol Metab. 85:720–726. 2000.PubMed/NCBI
9	Slemenda C, Longcope C, Peacock M, Hui S and Johnston CC: Sex steroids, bone mass, and bone loss. A prospective study of pre-, peri-, and postmenopausal women. J Clin Invest. 97:14–21. 1996. View Article : Google Scholar : PubMed/NCBI
10	Wolff I, van Croonenborg JJ, Kemper HC, Kostense PJ and Twisk JW: The effect of exercise training programs on bone mass: a meta-analysis of published controlled trials in pre- and postmenopausal women. Osteoporos Int. 9:1–12. 1999. View Article : Google Scholar : PubMed/NCBI
11	Clowes JA, Riggs BL and Khosla S: The role of the immune system in the pathophysiology of osteoporosis. Immunol Rev. 208:207–227. 2005. View Article : Google Scholar : PubMed/NCBI
12	Cavalli L and Brandi ML: Age- and gender-related macro- and micro-architecture changes in bone structure and implications for treatment. Int J Clin Rheumatol. 6:359–369. 2011. View Article : Google Scholar
13	Sanders S and Geraci SA: Osteoporosis in postmenopausal women: Considerations in prevention and treatment: (Women's health series). South Med J. 106:698–706. 2013. View Article : Google Scholar : PubMed/NCBI
14	Hofbauer LC, Brueck CC, Singh SK and Dobnig H: Osteoporosis in patients with diabetes mellitus. J Bone Miner Res. 22:1317–1328. 2007. View Article : Google Scholar : PubMed/NCBI
15	Leidig-Bruckner G and Ziegler R: Diabetes mellitus a risk for osteoporosis? Exp Clin Endocrinol Diabetes. 109(Suppl 2): S493–S514. 2001. View Article : Google Scholar : PubMed/NCBI
16	McLean RR: Proinflammatory cytokines and osteoporosis. Curr Osteoporos Rep. 7:134–139. 2009. View Article : Google Scholar : PubMed/NCBI
17	Huh JE, Lee WI, Kang JW, Nam D, Choi DY, Park DS, Lee SH and Lee JD: Formononetin attenuates osteoclastogenesis via suppressing the RANKL-induced activation of NF-κB, c-Fos, and nuclear factor of activated T-cells cytoplasmic 1 signaling pathway. J Nat Prod. 77:2423–2431. 2014. View Article : Google Scholar : PubMed/NCBI
18	Oh KW: Diabetes and Osteoporosis. Korean Diabetes J. 33:169–177. 2009.In Korean. View Article : Google Scholar
19	Zheng M, Ge Y, Li H, Yan M, Zhou J and Zhang Y: Bergapten prevents lipopolysaccharide mediated osteoclast formation, bone resorption and osteoclast survival. Int Orthop. 38:627–634. 2014. View Article : Google Scholar :
20	Perez RM: Anti-inflammatory activity of compounds isolated from plants. Scientific World Journal. 1:713–784. 2001. View Article : Google Scholar
21	Peng X, Nie Y, Wu J, Huang Q and Cheng Y: Juglone prevents metabolic endotoxemia-induced hepatitis and neuroinflammation via suppressing TLR4/NF-κB signaling pathway in high-fat diet rats. Biochem Biophys Res Commun. 462:245–250. 2015. View Article : Google Scholar : PubMed/NCBI
22	Holstein P, Ellitsgaard N, Olsen BB and Ellitsgaard V: Decreasing incidence of major amputations in people with diabetes. Diabetologia. 43:844–847. 2000. View Article : Google Scholar : PubMed/NCBI
23	Romero-Aroca P: Managing diabetic macular edema: The leading cause of diabetes blindness. World J Diabetes. 2:98–104. 2011. View Article : Google Scholar : PubMed/NCBI
24	Shoji T, Emoto M, Shinohara K, Kakiya R, Tsujimoto Y, Kishimoto H, Ishimura E, Tabata T and Nishizawa Y: Diabetes mellitus, aortic stiffness, and cardiovascular mortality in end-stage renal disease. J Am Soc Nephrol. 12:2117–2124. 2001.PubMed/NCBI
25	Schneider PA, Caps MT, Ogawa DY and Hayman ES: Intraoperative superficial femoral artery balloon angioplasty and popliteal to distal bypass graft: an option for combined open and endovascular treatment of diabetic gangrene. J Vasc Surg. 33:955–692. 2001. View Article : Google Scholar : PubMed/NCBI
26	Balkau B, Shipley M, Jarrett RJ, Pyörälä K, Pyörälä M, Forhan A and Eschwège E: High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care. 21:360–367. 1998. View Article : Google Scholar : PubMed/NCBI
27	Sumner CJ, Sheth S, Griffin JW, Cornblath DR and Polydefkis M: The spectrum of neuropathy in diabetes and impaired glucose tolerance. Neurology. 60:108–111. 2003. View Article : Google Scholar : PubMed/NCBI
28	Kim C, Newton KM and Knopp RH: Gestational diabetes and the incidence of type 2 diabetes: a systematic review. Diabetes Care. 25:1862–1868. 2002. View Article : Google Scholar : PubMed/NCBI
29	Moran C, Münch G, Forbes JM, Beare R, Blizzard L, Venn AJ, Phan TG, Chen J and Srikanth V: Type 2 diabetes, skin autofluorescence, and brain atrophy. Diabetes. 64:279–283. 2015. View Article : Google Scholar
30	Zinman B, Lachin JM and Inzucchi SE: Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 374:10942016.PubMed/NCBI
31	Wu YY, Xiao E and Graves DT: Diabetes mellitus related bone metabolism and periodontal disease. Int J Oral Sci. 7:63–72. 2015. View Article : Google Scholar : PubMed/NCBI
32	Li R, Xu W, Luo S, Xu H, Tong G, Zeng L, Zhu D and Weng J: Effect of exenatide, insulin and pioglitazone on bone metabolism in patients with newly diagnosed type 2 diabetes. Acta Diabetol. 52:1083–1091. 2015. View Article : Google Scholar : PubMed/NCBI
33	Wu QQ, Xu M, Yuan Y, Li FF, Yang Z, Liu Y, Zhou MQ, Bian ZY, Deng W, Gao L, et al: Cathepsin B deficiency attenuates cardiac remodeling in response to pressure overload via TNF-α/ASK1/JNK pathway. Am J Physiol Heart Circ Physiol. 308:H1143–H1154. 2015. View Article : Google Scholar : PubMed/NCBI
34	Weston CR and Davis RJ: The JNK signal transduction pathway. Curr Opin Cell Biol. 19:142–149. 2007. View Article : Google Scholar : PubMed/NCBI